WATERTOWN, Mass. -- (BUSINESS WIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, today announced presentations at two upcoming investor conferences. The Company’s lead antibiotic candidate, eravacycline, is currently in Phase 3 development for use as a potential first-line monotherapy for the treatment of multidrug-resistant (MDR) infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 26th Annual ROTH Conference on Tuesday, March 11 at 8:00 a.m. Pacific Time. The conference will take place at The Ritz Carlton in Laguna Niguel, CA.
Mr. Macdonald will also be presenting at the Barclays Global Healthcare Conference on Wednesday, March 12 at 4:15 p.m. Eastern Time. The conference will take place at the Loews Miami Hotel in Miami.
Live audio webcasts of the presentations will be available on the Company’s website at http://ir.tphase.com/events.cfm. Archived presentations will be available for 90 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being studied in a Phase 3 clinical program as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability. Please visit www.tphase.com for more company information.